Features and properties of sparsentan

Alternative names	DEARA; FILSPARI; PS-433540; RE-021
Class	Anti-inflammatories; antihypertensives; isoxazoles; nerve growth factors; small molecules; spiro compounds; sulfonamides; urologics; vascular disorder therapies
Mechanism of action	Angiotensin II type 1 receptor antagonists; endothelin type A receptor antagonists
Route of administration	Oral
Pharmacodynamics	Shows nephroprotective effects in rodent models of IgA nephropathy and focal segmental glomerulosclerosis
Pharmacokinetics	Less than dose-proportional, time-dependent pharmacokinetics; time to peak plasma concentration ≈ 3 h; volume of distribution 61.4 L; apparent clearance 5.11 L/h; half-life 9.6 h
Most frequent adverse events	Peripheral oedema, hypotension (including orthostatic hypotension), dizziness, hyperkalaemia, anaemia
ATC codes
WHO ATC code	G04B-X (Other Urologicals)
EphMRA ATC code	G4X (All Other Urological Products)
Chemical name	4′-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide